Peptide vaccine targets H3K27M mutation in midline gliomas, shows promise in early trials

#Peptide #vaccine #targets #H3K27M #mutation #midline #gliomas #shows #promise #early #trials

Researchers from Heidelberg and Mannheim have successfully treated adult patients with difficult-to-treat brain tumors using a peptide vaccine for the first time. The vaccine targeted a mutational change in a histone protein that is typical of this type of cancer. The vaccine was proven to be safe and induced desired immune responses against the brain tumor. The researchers reconstructed the mutated section of the histone H3 protein and successfully slowed the growth of tumors in a mouse model. In a phase I trial, eight adult patients with the same mutation were treated with the vaccine and showed immune responses against the mutant protein. Further research is ongoing.



Source link